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Overview
ABC 4, the fourth annual open forum on agricultural biotechnology,
was devoted to issues in animal biotechnology. The May 1992 meeting 
was held in College Station, Texas and hosted by Texas A&M University. 
Animal well-being, the safety of animal food products and regulatory issues 
were on the agenda along with the examination of links between animal bio-
technology and new opportunities in human and animal medicine. Previous 
NABC meetings had focused upon sustainability, food safety and quality, 
and the financial and regulatory prospects for agricultural biotechnology at a 
crossroads. Animal biotechnology, especially recombinant DNA research on 
agricultural animals, however, has opened doors to entirely new areas of hu-
man endeavor, many of which were not well understood in the past. The 
NABC 4 presentations and discussions on animal biotechnology revisited 
several themes that had been discussed at previous NABC meetings, but also 
broke ground in identifying several key topics that had not been examined 
at Ames, Iowa in 1989; at Ithaca, New York in 1990; and at Sacramento, Cali-
fornia in 1991.
As in previous meetings, the aim of the National Agricultural Biotech-
nology Council was first and foremost to establish an open setting in which 
all perspectives and interests can be represented with participants sharing 
ideas, asking questions and interacting with one another. Convening under 
the banner Animal Biotechnology: Opportunities and Challenges, more than 
150 representatives of industry, interest groups, government and universities 
opened the conversation on these topics with the goals of establishing a com-
mon base of knowledge among all participants, reaching consensus where 
possible, and specifying a limited number of recommendations to emerge 
as the product of the workshops. NABC 4 continued the trend of the three 
previous meetings by expanding the range of views and groups represented. 
Many of the participants, particularly those concerned with issues of animal 
well-being, were attending this open forum for the first time. Also, some par-
ticipants were presented for the first time with viewpoints in sharp contrast 
to their own. For this reason alone, NABC 4 clearly can be said to have served 
the NABC mission of promoting dialogue among those with different views.
NEW THEMES
The new topic to the NABC forum was the linkages between human medicine 
and animal agriculture. Although animal biotechnology was addressed at 
NABC 1 and at NABC 3, animal well-being as a special theme was a new fo-
cus for NABC.
Animal Well-Being
The dialogue on animal well-being had been conceptualized as an opportu-
nity to take up the question of whether developments in animal biotechnol-
ogy would produce any new or unanticipated issues for the well-being of ag-
ricultural animals. Although these topics were, indeed, discussed, presenta-
tions by keynoter Michael Fox, Vice President for Bioethics and Farm Ani-
mals, The Humane Society of the United States; David Meeker, Director of 
Research and Education, National Pork Producers Council; and Bernard 
Rollin, Professor of Philosophy at Colorado State University, moved the dis-
cussions into more philosophical and broad-ranging areas. This workshop 
became a forum in which those who saw themselves as representing animals 
and those who saw themselves as representing agriculture engaged in ener-
getic dialogue over the criteria and basis for extending concern to animals, 
without respect to whether biotechnology or, indeed, even agriculture was 
the topic of concern. As such, participants raised examples from human bio-
medical research and product testing, familiar forums for animal welfare de-
bates, as a means for sounding out each other’s basic views on animal issues.
The question of biomedical applications came up particularly with the 
“new creation” of: 1. precise animal models for human diseases; and 2. ani-
mals as “bioreactors” producing human pharmaceuticals. Rollin prompted a 
discussion of the dilemma of balancing the relief of great human pain and 
suffering from genetic diseases with the large numbers of animals that would 
experience great suffering. He suggested researchers could eliminate the pain 
centers of such animals, but noted that this, too, raises ethical and aesthetic 
concerns.
Although the heated discussions in this group produced limited con-
sensus, there was general agreement that it is acceptable under conditions 
where animals do not experience great suffering, to use animals for human 
use—whether for food production, as “bioreactors,” or as research models 
for improving human and animal health.
The intensity of discussions in the group was evident to all meeting par-
ticipants and issues of animal well-being wound up being raised (sometimes 
briefly) in every workshop. In the shadow of such lively dialogue, the work-
shop group examining links to human health felt itself to be too homoge-
neous with few issues on which participants opinions diverged. The group 
invited a participant from the animal well-being workshop to a session to 
learn, at least, what the hubbub was about. Although the agenda was broader,
Animal Biotechnology: Opportunities & Challenges
and the consensus achievements occurred in other areas, the 1992 meeting 
will undoubtedly be remembered as the “animal welfare” meeting of the Na-
tional Agricultural Biotechnology Council.
Links to Human Health
Recombinant DNA research on farm animals conducted in animal science 
departments of agricultural universities and in colleges of veterinary medi-
cine, has begun to bring the scientists in these areas into the prospects and 
controversies that have traditionally been associated with biomedical re-
search. As highlighted by keynote speaker Neal First, Professor of Animal 
Science at the University of Wisconsin, animal biotechnology continues to 
establish breakthroughs in reproductive technology, enhance genetic 
changes in animals and improve animal health. He conveyed to the partici-
pants some of the excitement felt by researchers, himself included, as they 
push the frontiers of animal science forward. It was noted that basic research 
aimed at disease control in animals often spills over to human applications. 
Fuller Bazer, Animal Science Department, Texas A&M University, asserted 
that “When human and animals have diseases with common etiology and ge-
netic markers of the disease, genetic or therapeutic solutions will favorably 
impact both human and animal health.” What is more, Clifton Baile, Direc-
tor of Research and Development at Monsanto, suggested that intensive pub-
lic and private funding for research in biomedical applications such as gene 
mapping and pharmaceuticals will produce techniques, methods and models 
that will shorten the time for product development for those working on 
farm animals.
The workshop participants actively discussed the need for connections, 
or “new linkages,” between human medicine, animal medicine and animal 
agriculture. They saw a major potential for expanding the dialogue and re-
search interaction among these groups, suggesting that soon the justification 
for animal biotechnology may be its great benefits to human health, not just 
animal productivity.
It was, however, noted that as agricultural researchers expand their re-
search and interact directly, or even indirectly, with biomedical researchers, 
they can expect to face some of the problems that have existed in public 
health and the biomedical research policy arena for some time. These include 
an intense public interest in reproductive technologies, in part because of 
their relevance to the abortion issue, and also a level of public concern for 
the well-being of animals exceeding that hitherto experienced in connection 
with food animals. As such, the workshop on animal well-being experienced 
an overlap with the workshop on animal biotechnology links to human 
health that meeting organizers had not anticipated. When continuing discus-
sions on food safety and regulatory policy were added into the mix, the two- 
plus days of the meeting proved stimulating.
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REVISITED THEMES 
Communication and Open Dialogue
The only issue that could rival animal well-being as a main current at the 
1992 meeting was the continued call from participants for open communica-
tion and the need for all stakeholders to be involved early and continuously 
in the dialogue on biotechnology. The highly publicized White House an-
nouncement of the FDA’s policy for evaluating the safety of foods of plant 
origin made on May 26, 1992, the day before the meeting began, resulted in 
several diverse groups in attendance at NABC 4 openly expressing concern 
that if biotechnology is to gain public acceptance, policies must be developed 
within an open framework with opportunity for input by all interested stake-
holders. While most in attendance were not against the announced policy per 
se, participants on “both” sides of other biotechnology issues followed press 
coverage of the announcement all week, expressing the view that the an-
nouncement reflected little understanding of how public concerns and ques-
tions about biotechnology can be addressed in a manner that inspires confi-
dence in the regulatory process.
At the final plenary session, in response to a recommendation by the 
participants in the Regulatory Issues workshop, several participants spoke 
forcefully in favor (no one spoke in opposition) of NABC corresponding 
with appropriate federal officials urging more open dialogue during future 
deliberations about agricultural biotechnology policies.1
Ironically, the announcement of this policy spoke directly to two of the 
concerns expressed as major themes of the 1991 NABC meeting in California. 
There, U.S. competitiveness had been linked to a need for clear delineation 
of regulatory procedures for research and product development. The policy 
which was, in fact, being announced for comment, was a response to both 
themes.
The two overarching currents of NABC 4—animal welfare and the call 
for open dialogue—point toward reiteration of a conclusion that was 
reached at the 1990 NABC meeting in New York State: concerned parties in 
the food arena have failed to talk with each other, much less communicate. 
Regrettably, much the same conclusion was reached by the 1992 workshop 
on Meat and Animal Product Safety. Participants were in strong agreement 
that differing groups fail to interact and called on scientists to begin to com-
municate with the public as equal partners.
Defining Food Safety
This failure to interact and communicate became evident in discussions on 
how to define safety. There were those, mostly scientists, responding to the
1 Editor’s note: Letters were sent to Vice President Quayle and the heads of HHS, 
FDA, EPA and USDA expressing NABC’s belief that the acceptance of government 
efforts by the public can be enhanced only when policies are developed and per-
ceived to be developed with appropriate input from all interested parties.
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presentations of David Berkowitz, Office of Biotechnology, FDA; Russell 
Cross, Administrator, USDA/FSIS; and John Frydenlund, Deputy Assistant 
Secretary, Marketing and Inspection at USDA, who felt that safety should be 
defined in terms of whether eating a product will cause injury or disease. 
They urged that scientific principles be used to; 1. assess the probability of 
foodborne injury to health; and 2. target foods where alterations associated 
with biotechnology might increase the probability of harm (e.g., allergenicity). 
A second view was represented by Dianna Hunter, a former small farmer and 
member of the Minnesota Food Association, who interpreted safety as “feel-
ing confident about one’s food.” Factors that influence such confidence in-
clude whether the food is being produced and provided through a trustwor-
thy source. Many participants agreed that nonscience factors (e.g., social, 
economic) can influence whether a source is deemed trustworthy and should 
be considered in the assessment of foodborne risk.
The 1992 meeting illustrated the need for biotechnology industries and 
high-level government officials to get behind the goal of increasing two-way 
communication where biotechnologists listen to the nature and shape of 
public and interest group concerns before formulating their messages about 
the safety, efficacy and benefits of biotechnology.
Regulatory Policy
A recurring theme in all the workshops was the need for clear regulatory 
policies for agricultural biotechnology whether for food, pharmaceuticals or 
animal use or release. In the workshop on Regulatory Issues, participants felt 
that pharmaceutical products have been foremost in the thinking of regula-
tors who have concluded that the existing framework for biotechnology 
regulation is adequate and that all forms of regulation should stress product 
over process. Martin Terry, Vice President for Scientific Activities, Animal 
Health Institute, expressed the frustration of industry faced with different 
regulations depending on product classification as a drug or a food. He called 
the groups attention to both the debate on extra-label drug use in animals 
and the crisis in drug availability which currently besets animal agriculture. 
From the environmental perspective Margaret Mellon, Director, National 
Biotechnology Policy Center, National Wildlife Federation, argued a need 
for regulatory action, noting that there are several areas, including fish and 
wildlife, where animal scientists are undertaking biotechnology research in 
the absence of clear regulatory authority.
The group also discussed how process and point of origin have tradi-
tionally been important to consumer acceptance of agricultural products. 
Virtually every state claims that its soils, climate and farmers produce the 
best potatoes, onions, wine, pork or something. Furthermore, it was noted 
that the Food Safety Inspection Service (FSIS) has made decisions based 
on judgements that are not supported by risk-based reasons. For example, 
FSIS does not allow lungs to be used in meat products based on the cultural
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judgement that consumers do not want meat products in which lungs are 
used—in the U.S. lungs are not classified as food. As such, participants felt 
that a decision to consider only risk-based regulatory policies for agricul-
tural biotechnology leaves many questions unanswered, for example, label-
ing and product certification—another continuing theme that emerged in 
each workshop only to be shelved by each noting the need for a future NABC 
forum on the issue of labeling of biotechnology food products.
The 1992 meeting explored new issues and revisited several continuing 
issues. NABC 4 established a series of key understandings that should shape 
the direction of animal biotechnology research, product development, policy 
and administration for the coming decade. There was overwhelming consen-
sus that greater public understanding of biotechnology processes and prod-
ucts and greater public participation in the decision-making process was not 
only desired, but essential, if agricultural biotechnology is, indeed, to be the 
growth industry of the 21st century.
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